liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
The potential legacy of cancer nanotechnology: celluar selection
Linköping University, Department of Physics, Chemistry and Biology, Biosensors and Bioelectronics. Linköping University, The Institute of Technology. Linköping University, Department of Clinical and Experimental Medicine, Division of Cell Biology. Linköping University, Faculty of Health Sciences.
Linköping University, Department of Physics, Chemistry and Biology, Biosensors and Bioelectronics. Linköping University, The Institute of Technology.
2014 (English)In: Trends in Biotechnology, ISSN 0167-7799, E-ISSN 1879-3096, Vol. 32, no 1, 21-31 p.Article, review/survey (Refereed) Published
Abstract [en]

Overexpression of oncogenes or loss of tumour suppressors can transform a normal cell to a cancerous one, resulting in uncontrolled regulation of intracellular signalling pathways and immunity to stresses, which both pose therapeutic challenges. Conventional approaches to cancer therapy, although they are effective at killing cancer cells, may still fail due to inadequate biodistribution and unwanted side effects. Nanotechnology-based approaches provide a promising alternative, with the possibility of targeting cells at an early stage, during their transformation into cancer cells. This review considers techniques that specifically target those molecular changes, which begin in only a very small percentage of normal cells as they undergo transformation. These techniques are crucial for early-stage diagnosis and therapy.

Place, publisher, year, edition, pages
Elsevier , 2014. Vol. 32, no 1, 21-31 p.
Keyword [en]
Cancer detection and therapy; Chemotherapy; Controlled drug release; Nanoparticles; Magic bullet; Multidrug resistance
National Category
Engineering and Technology Basic Medicine
Identifiers
URN: urn:nbn:se:liu:diva-104126DOI: 10.1016/j.tibtech.2013.10.004ISI: 000329771900004OAI: oai:DiVA.org:liu-104126DiVA: diva2:694668
Available from: 2014-02-07 Created: 2014-02-07 Last updated: 2017-12-06

Open Access in DiVA

fulltext(1176 kB)527 downloads
File information
File name FULLTEXT01.pdfFile size 1176 kBChecksum SHA-512
309d18b985769f4282f1e54fe3d7487e3f9664a85fa76af617d3228f0fcf899f9f2ddf7a24ed9fb2f8642ce71d8b9e0a5d549db935426bc45d6a4491254b75fe
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Authority records BETA

Patra, Hirak K.Turner, Anthony

Search in DiVA

By author/editor
Patra, Hirak K.Turner, Anthony
By organisation
Biosensors and BioelectronicsThe Institute of TechnologyDivision of Cell BiologyFaculty of Health Sciences
In the same journal
Trends in Biotechnology
Engineering and TechnologyBasic Medicine

Search outside of DiVA

GoogleGoogle Scholar
Total: 527 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 285 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf